Reforming the FDA

June 6, 1997 • Volume 7, Issue 21
Does the agency act too slowly?
By Richard L. Worsnop

Introduction

An FDA inspector checks the cleanliness of a compounding tank at a Baltimore drug plant.  (Photo Credit: Food and Drug Administration)
An FDA inspector checks the cleanliness of a compounding tank at a Baltimore drug plant.  (Photo Credit: Food and Drug Administration)

The Food and Drug Administration rarely has a shortage of critics. That's not surprising considering the agency's extraordinary role in American life: 25 cents of every consumer dollar is spent on FDA-regulated products.Much of the criticism leveled at the agency in recent years centered on its activist chief, David A. Kessler, who recently resigned to head theYale University Medical School. Just before leaving, Kessler refocused the spotlight on the FDA with his bid to regulate tobacco. Whoever is chosen as Kessler's successor likely will face close scrutiny during Senate confirmation hearings. Other FDA issues before Congress include reauthorization of the Prescription Drug User-Fee Act, credited with speeding approval of proposed new drugs, and bills to streamline other FDA procedures.

ISSUE TRACKER for Related Reports
Libraries
Jul. 29, 2011  Future of Libraries
Mar. 16, 2007  Presidential Libraries
Jun. 01, 2001  Libraries and the Internet
Jun. 06, 1997  Reforming the FDA
May 23, 1997  The Future of Libraries
Jun. 26, 1992  Hard Times for Libraries
Nov. 09, 1979  Libraries' Financial Squeeze
Jun. 02, 1967  Library Expansion
BROWSE RELATED TOPICS:
Nutrition
Smoking